For stage III+IV were the corresponding values respectively 96.5% and 91.6%, suggesting that the three-biomarker panel classified early-stage cancers with 94% sensitivity at 95% specificity, which was significantly higher than CA125 alone. Here, MUC16 is linked to cancer.